NASDAQ:ATEC

Alphatec Stock Forecast, Price & News

$17.60
+0.22 (+1.27 %)
(As of 04/9/2021 12:00 AM ET)
Add
Compare
Today's Range
$17.11
Now: $17.60
$18.00
50-Day Range
$15.10
MA: $16.49
$18.78
52-Week Range
$3.38
Now: $17.60
$19.36
Volume470,036 shs
Average Volume715,617 shs
Market Capitalization$1.67 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.53
Alphatec Holdings, Inc., a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders. The company offers SafeOp Neural InformatiX System, an Alpha InformatiX product platform designed to reduce the risk of intraoperative nerve injury; squadron lateral retractor designed to maximize patient outcomes; Sigma transforaminal lumbar interbody fusion pedicle-based access system that provides direct visualization of anatomical landmarks; Sigma PTP Access and Patient Positioning System; Invictus Spinal Fixation System, a thoracolumbar fixation system to treat a range of pathologies; and Invictus MIS SingleStep System designed to improve surgical efficiency without compromising accuracy. It also provides Invictus Modular Fixation Systems designed to increase adaptability with the power of screw modularity; OsseoScrew system to restore the integrity of the spinal column; Arsenal spinal fixation system, a comprehensive thoracolumbar fixation platform to fix a range of degenerative to deformity pathologies and surgical procedures; Aspida Anterior Lumbar Plating System, a fixation system for anterior lumbar interbody fusion; AMP Anti-Migration Plate; solanas posterior cervico/thoracic fixation system and avalon occipital plate; OCT Spinal Fixation System; trestle luxe anterior cervical plate system; and Insignia Anterior Cervical Plate System. In addition, the company offers IdentiTi Porous Ti, Transcend Lateral, and Battalion Posterior Interbody Implants; and biologics consisting of Cervical Structural Allograft Spacers, 3D ProFuse Demineralized Bone Scaffold, Neocore Osteoconductive Matrix, Alphagraft Demineralized and Cellular Bone Matrix, and Amnioshield Amniotic Tissue Barrier. Further, it develops EOS imaging products. It sells its products through a network of independent distributors and direct sales representatives in the United States. The company was founded in 1990 and is based in Carlsbad, California.
Alphatec logo

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
Current SymbolNASDAQ:ATEC
CUSIP02081G10
Phone760-431-9286
Employees296
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$113.43 million
Book Value$0.71 per share

Profitability

Net Income$-57,000,000.00

Miscellaneous

Market Cap$1.67 billion
Next Earnings Date5/10/2021 (Estimated)
OptionableNot Optionable

Headlines

Return On Capital Employed Overview: Alphatec Holdings
April 8, 2021 |  feeds.benzinga.com
Alphatec (NASDAQ:ATEC) Shares Gap Up to $15.60
April 8, 2021 |  americanbankingnews.com
Alphatec (NASDAQ:ATEC) Stock Price Up 6.5%
April 6, 2021 |  americanbankingnews.com
Alphatec (NASDAQ:ATEC) Shares Down 4.1%
March 26, 2021 |  americanbankingnews.com
Alphatec (NASDAQ:ATEC) Shares Up 2.9%
March 23, 2021 |  americanbankingnews.com
ATEC Announces Memphis Distribution Facility
March 23, 2021 |  finance.yahoo.com
Alphatec (NASDAQ:ATEC) Hits New 52-Week High at $19.22
March 22, 2021 |  americanbankingnews.com
See More Headlines

MarketRank

Overall MarketRank

0.83 out of 5 stars

Medical Sector

1174th out of 2,010 stocks

Surgical & Medical Instruments Industry

106th out of 168 stocks

Analyst Opinion: 1.5Community Rank: 2.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
$17.60
+0.22 (+1.27 %)
(As of 04/9/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ATEC News and Ratings via Email

Sign-up to receive the latest news and ratings for ATEC and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Alphatec (NASDAQ:ATEC) Frequently Asked Questions

Is Alphatec a buy right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Alphatec in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Alphatec stock.
View analyst ratings for Alphatec
or view top-rated stocks.

What stocks does MarketBeat like better than Alphatec?

Wall Street analysts have given Alphatec a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Alphatec wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Alphatec?

Alphatec saw a decline in short interest in the month of March. As of March 15th, there was short interest totaling 1,990,000 shares, a decline of 41.1% from the February 28th total of 3,380,000 shares. Based on an average trading volume of 774,800 shares, the days-to-cover ratio is presently 2.6 days.
View Alphatec's Short Interest
.

When is Alphatec's next earnings date?

Alphatec is scheduled to release its next quarterly earnings announcement on Monday, May 10th 2021.
View our earnings forecast for Alphatec
.

How were Alphatec's earnings last quarter?

Alphatec Holdings, Inc. (NASDAQ:ATEC) released its earnings results on Thursday, March, 4th. The medical technology company reported ($0.35) EPS for the quarter, missing the Zacks' consensus estimate of ($0.23) by $0.12. The medical technology company had revenue of $43.95 million for the quarter, compared to the consensus estimate of $43.87 million. Alphatec had a negative trailing twelve-month return on equity of 266.45% and a negative net margin of 51.95%.
View Alphatec's earnings history
.

How has Alphatec's stock price been impacted by COVID-19 (Coronavirus)?

Alphatec's stock was trading at $4.41 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, ATEC stock has increased by 299.1% and is now trading at $17.60.
View which stocks have been most impacted by COVID-19
.

What guidance has Alphatec issued on next quarter's earnings?

Alphatec updated its first quarter 2021 IntraDay earnings guidance on Thursday, April, 8th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $43.7-44.1 million, compared to the consensus revenue estimate of $39.45 million.

What price target have analysts set for ATEC?

7 brokerages have issued 1-year price targets for Alphatec's stock. Their forecasts range from $9.00 to $20.00. On average, they anticipate Alphatec's stock price to reach $15.43 in the next year. This suggests that the stock has a possible downside of 12.3%.
View analysts' price targets for Alphatec
or view top-rated stocks among Wall Street analysts.

Who are Alphatec's key executives?

Alphatec's management team includes the following people:
  • Mr. Patrick S. Miles, Exec. Chairman, CEO & Pres (Age 55, Pay $1.23M)
  • Mr. Jeffrey G. Black, Exec. VP & CFO (Age 52, Pay $652.76k)
  • Mr. David P. Sponsel, Exec. VP of Sales (Age 42, Pay $768.18k)
  • Mr. Scott Lish, Sr. VP of R&D
  • Mr. Craig E. Hunsaker, Exec. VP of People & Culture, Corp. Sec. and Gen. Counsel (Age 57)
  • Mr. Brian R. Snider, Exec. VP of Marketing & Devel. (Age 43)
  • Mr. Jonathan Allen, Exec. VP of Commercial Operations (Age 61)
  • Dr. Luiz Pimenta, Chief Medical Officer
  • Ms. Kelli Mari Howell, Exec. VP of Clinical Strategies (Age 47)
  • Mr. Mark D. Ojeda, Exec. VP of Cervical & Biologics (Age 51)

What is Pat Miles' approval rating as Alphatec's CEO?

7 employees have rated Alphatec CEO Pat Miles on Glassdoor.com. Pat Miles has an approval rating of 72% among Alphatec's employees.

Who are some of Alphatec's key competitors?

What other stocks do shareholders of Alphatec own?

What is Alphatec's stock symbol?

Alphatec trades on the NASDAQ under the ticker symbol "ATEC."

How do I buy shares of Alphatec?

Shares of ATEC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Alphatec's stock price today?

One share of ATEC stock can currently be purchased for approximately $17.60.

How much money does Alphatec make?

Alphatec has a market capitalization of $1.67 billion and generates $113.43 million in revenue each year. The medical technology company earns $-57,000,000.00 in net income (profit) each year or ($1.09) on an earnings per share basis.

How many employees does Alphatec have?

Alphatec employs 296 workers across the globe.

What is Alphatec's official website?

The official website for Alphatec is www.atecspine.com.

Where are Alphatec's headquarters?

Alphatec is headquartered at 5818 EL CAMINO REAL, CARLSBAD CA, 92008.

How can I contact Alphatec?

Alphatec's mailing address is 5818 EL CAMINO REAL, CARLSBAD CA, 92008. The medical technology company can be reached via phone at 760-431-9286 or via email at [email protected]


This page was last updated on 4/10/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.